{"filings":[{"id":1139327,"accession_number":"0001861560-26-000023","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-06-18T20:30:29+00:00","items":["5.07"],"status":"ready","headline":"Nuvalent stockholders elect two Class II directors, approve executive compensation and auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael L. Meyers elected with 57,592,636 for/13,110,466 against; Ron Squarer with 70,612,828 for/90,274 against.","Advisory vote on named executive officer compensation approved: 68,898,711 for, 1,786,465 against.","Ratification of KPMG as independent auditor for FY2026 passed: 71,172,889 for, 858 against.","96.80% of outstanding shares represented at the June 16, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927396,"accession_number":"0001193125-26-262950","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-06-09T11:03:35+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"GSK to acquire Nuvalent for $124/share (~$10.6B); assets under FDA review for 2026 approval","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-share tender offer at $124.00 per share; aggregate equity value ~$10.6B; net cash investment ~$9.4B.","40% premium to last closing price; 26% premium to 30-day VWAP; no financing condition.","Deal includes late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib; FDA decisions due Sept/Nov 2026.","Supporting stockholders (~28% of Class A shares) have agreed to tender; termination fee $350.5M.","Transaction expected to close Q3 2026; GSK expects accretion to operating profit in 2027, EPS in 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96358,"accession_number":"0001861560-26-000020","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent submits NDA for neladalkib in ALK+ NSCLC; zidesamtinib PDUFA Sept 18, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDA for neladalkib in TKI pre-treated ALK+ NSCLC submitted; pivotal data at ASCO 2026.","Zidesamtinib NDA under FDA review; PDUFA target action date September 18, 2026.","Plan to submit data in 2H 2026 for zidesamtinib label expansion in TKI-naïve ROS1+ NSCLC.","Cash $1.3B; net loss $109.3M in Q1 2026 (R&D $83.6M, G&A $35.8M).","Leadership promotions: Dr. Benjamin Lane to Chief Technology Operations Officer; Dr. Kirsten Duncan to VP Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96357,"accession_number":"0001861560-26-000003","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent submits NDA to FDA for neladalkib in ALK-positive lung cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted to FDA on April 7, 2026, for neladalkib in TKI pre-treated advanced ALK-positive NSCLC.","Neladalkib is a novel ALK inhibitor targeting advanced ALK+ non-small cell lung cancer.","Submission marks regulatory milestone; no additional details on acceptance or review timeline provided.","Nuvalent (NUVL) expects FDA review of the NDA for potential market approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110189,"accession_number":"0001193125-26-073304","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q4 and FY2025 net loss; zidesamtinib PDUFA set for Sept 18, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $118.7M in Q4 2025 and $425.4M for full year 2025.","Cash, equivalents and marketable securities of $1.4B, runway into 2029.","FDA accepted zidesamtinib NDA; PDUFA target action date September 18, 2026.","NDA submission for neladalkib in ALK+ NSCLC planned first half 2026.","Closed $500M public offering of common stock in November 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110188,"accession_number":"0001193125-26-012243","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports $1.4B cash, zidesamtinib PDUFA Sep 18, 2026; pipeline milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and securities ~$1.4B as of Dec 31, 2025; runway into 2029.","FDA accepted NDA for zidesamtinib in TKI pre-treated ROS1+ NSCLC; PDUFA Sep 18, 2026.","NDA submission for neladalkib in TKI pre-treated ALK+ NSCLC planned for H1 2026.","Potential indication expansion submission for zidesamtinib in TKI-naïve ROS1+ NSCLC in H2 2026.","Progressing ALKAZAR Phase 3 (neladalkib, TKI-naïve ALK+) and HEROEX-1 Phase 1a/1b (NVL-330, HER2-altered NSCLC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126751,"accession_number":"0001193125-25-320150","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.","The deal value is up to $315 million; Nuvalent is not a party to the transaction.","Nuvalent clarifies the 'low single digit preexisting royalty' is exactly 1.5% of net sales of both candidates.","Nuvalent's revenue share agreement with its scientific founder remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126750,"accession_number":"0001193125-25-314165","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvalent director Matthew Shair resigns; Ron Squarer elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Shair, Ph.D., resigned from the Board effective Dec 9, 2025, and not due to any disagreement.","Ron Squarer elected as Class II independent director effective Dec 10, 2025, until 2026 annual meeting.","Squarer receives initial equity award with aggregate fair value $600,000 (option + RSU).","Option capped at 14,850 shares, RSU capped at 7,425 shares; vesting over 3 years.","Squarer eligible for annual director cash retainers and committee fees per policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126749,"accession_number":"0001193125-25-288770","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvalent prices $500M public offering at $101/share; net proceeds ~$472M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 4,950,496 shares at $101.00/share for gross proceeds of ~$500M.","Net proceeds to Nuvalent of ~$471.9M after underwriting discounts and expenses.","Selling stockholders (Deerfield funds) have 30-day option to sell 742,574 additional shares; Nuvalent receives no proceeds.","Closing expected on November 20, 2025; net proceeds plus existing cash expected to fund operations into 2029.","Joint book-running managers: J.P. Morgan, Jefferies, TD Cowen, and Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126748,"accession_number":"0001193125-25-283893","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent reports positive pivotal data for neladalkib in ALK+ NSCLC; ORR 31% in TKI pre-treated, 46% in lorlatinib-naïve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neladalkib achieved 31% ORR (79/253) in TKI pre-treated ALK+ NSCLC; median DOR not reached at 11.3 months follow-up.","In lorlatinib-naïve subset (n=63), ORR 46% (29/63); DOR ≥12 months 80%. Intracranial ORR 63% with 21% CR.","Preliminary TKI-naïve cohort (n=44): ORR 86% (38/44), CR 9%, intracranial ORR 78% with 44% CR.","Safety consistent with ALK-selective design; most common TEAEs: ALT/AST elevations, constipation, dysgeusia. 5% discontinuation.","Company plans pre-NDA meeting with FDA for TKI pre-treated population; detailed results at future medical meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126747,"accession_number":"0001193125-25-257347","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent Q3 net loss $122.4M; completes NDA for zidesamtinib; cash $943M into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC.","On track to report topline pivotal data for neladalkib in ALK-positive NSCLC by year-end 2025.","Cash, cash equivalents and marketable securities of $943.1M as of Sept 30, 2025; expected runway into 2028.","Q3 2025 net loss of $122.4M, R&D expenses $83.8M, G&A expenses $28.9M.","Presented preliminary data for neladalkib in ALK-positive solid tumors at ESMO and preclinical data for NVL-330 in HER2-altered NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143539,"accession_number":"0001193125-25-209934","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent completes NDA submission to FDA for zidesamtinib in ROS1-positive NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed NDA submission to FDA for zidesamtinib.","Indication: TKI pre-treated advanced ROS1-positive non-small cell lung cancer.","Submission date: September 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143538,"accession_number":"0000950170-25-104531","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.","Rolling NDA for zidesamtinib (ROS1+ NSCLC) initiated; target completion Q3 2025; FDA RTOR pilot.","ALKAZAR Phase 3 of neladalkib (ALK+ NSCLC) dosed; topline TKI pre-treated data expected year-end 2025.","Preliminary data for neladalkib in ALK+ solid tumors at ESMO 2025 (Oct 17-21).","Jason Waters promoted to SVP Commercial; Christy Oliger appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143537,"accession_number":"0000950170-25-097069","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent initiates Phase 3 ALKAZAR trial of neladalkib in ALK-positive NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 3 ALKAZAR trial evaluating neladalkib for TKI-naïve advanced ALK-positive NSCLC.","Trial compares neladalkib head-to-head against ALECENSA (alectinib), a front-line standard of care.","ALKAZAR is a registrational study designed to support potential approval of neladalkib in this indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161733,"accession_number":"0000950170-25-089213","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent reports positive pivotal data for zidesamtinib in ROS1+ NSCLC; NDA submission set for July 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zidesamtinib achieved 44% ORR (51/117) in TKI pre-treated ROS1+ NSCLC; intracranial ORR 48% (27/56) with 20% complete responses.","In TKI-naïve cohort, preliminary ORR 89% (31/35) with intracranial ORR 83% (5/6) and 67% complete responses; 104 patients enrolled.","FDA agreed to RTOR for zidesamtinib; rolling NDA to start July 2025, completion targeted Q3 2025, for TKI pre-treated advanced NSCLC.","ALKAZAR Phase 3 trial of neladalkib vs alectinib in ALK+ NSCLC expected to begin enrollment early H2 2025.","Zidesamtinib well tolerated: 2% discontinued due to TEAEs; median exposure 5 months; common TEAEs included peripheral edema (36%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161732,"accession_number":"0000950170-25-088542","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Nuvalent elects Christy Oliger as new board member; 2025 annual meeting results disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christy J. Oliger elected to Board as Class III director, effective June 18, 2025; appointed to Audit Committee.","Ms. Oliger receives initial grant: option for 6,119 shares at $75.53, RSU for 3,971 shares, each vesting over 3 years.","Annual Meeting held June 18; 97.01% of shares represented. All three Class I director nominees elected: Bogle, Porter, Protopapas.","Advisory vote on exec comp approved (53.5M for, 10.4M against, 2.5K abstain). Ratification of KPMG as auditor approved (64.4M for, 10.8K against).","Broker non-votes: 500,127 on director and say-on-pay proposals; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161731,"accession_number":"0000950170-25-084385","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Emily Conley resigns from Nuvalent board effective at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Emily Conley notified Nuvalent of her resignation from the Board and all committees, effective at the 2025 annual meeting.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement announced; board size will be reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161730,"accession_number":"0000950170-25-066397","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q1 net loss $84.6M; reiterates zidesamtinib pivotal data in H1 2025, NDA by mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $1.1B at March 31, 2025; expected to fund operations into 2028.","Q1 net loss $84.6M; R&D expense $74.4M, G&A expense $20.4M.","Zidesamtinib pivotal data for TKI pre-treated ROS1+ NSCLC in H1 2025; NDA submission by mid-2025.","Neladalkib pivotal data for TKI pre-treated ALK+ NSCLC by year-end 2025; ALKAZAR Phase 3 start in H1 2025.","Leadership promotions: Ruth Adams to SVP Clinical Ops, Joshua Horan to SVP Chemistry, Jessie Lin to SVP Corporate Strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161729,"accession_number":"0000950170-25-055491","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director D. Gary Gilliland to resign from Nuvalent Board, join scientific advisory board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Gilliland notified Nuvalent of resignation effective at 2025 annual meeting.","Will enter consulting agreement to serve on scientific advisory board post-resignation.","Resignation not due to any disagreement on operations, policies, or practices.","Dr. Gilliland currently serves on Board and all committees; departure is planned transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179831,"accession_number":"0000950170-25-028323","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q4 net loss $74.8M, cash $1.1B; pivotal data on track for 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $74.8M (Q4 2024) and $260.8M (FY 2024); cash & equivalents $1.1B, expected to fund into 2028.","Pivotal data for zidesamtinib in TKI pre-treated ROS1+ NSCLC expected H1 2025; NDA submission mid-2025.","Pivotal data for neladalkib in TKI pre-treated ALK+ NSCLC expected year-end 2025; Phase 3 ALKAZAR initiating H1 2025.","Global Expanded Access Programs launched for zidesamtinib and neladalkib for eligible patients.","Appointed Grant Bogle, former Epizyme CEO, to Board of Directors in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179830,"accession_number":"0001193125-25-005629","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvalent Plans Initial NDA Submission for Zidesamtinib by Mid-2025 and Reports Pivotal Data Milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2024, 430 patients enrolled in ARROS-1 trial of zidesamtinib for ROS1-positive NSCLC.","As of Dec 31, 2024, 596 patients enrolled in ALKOVE-1 trial of neladalkib for ALK-positive NSCLC.","Topline pivotal data for zidesamtinib expected H1 2025; NDA submission for TKI pre-treated ROS1+ NSCLC by mid-2025.","Topline pivotal data for neladalkib (NVL-655) expected by year-end 2025; Phase 3 ALKAZAR trial to initiate H1 2025.","Nuvalent presented at 43rd Annual J.P. Morgan Healthcare Conference on Jan 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196589,"accession_number":"0001193125-24-272853","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuvalent elects Grant Bogle as new independent Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Grant Bogle elected to the Board effective Dec 5, 2024, as Class I director until 2025 annual meeting.","Initial equity grant: option for 4,851 shares at $93.73 (closing price) + RSU for 3,200 shares, both vesting over 3 years.","Bogle is independent per Nasdaq rules; will receive standard non-employee director cash and equity compensation.","Board also approved a new form of PSU award agreement for performance-vesting RSUs under the 2021 Stock Option and Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196588,"accession_number":"0000950170-24-124514","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q3 net loss $84.3M; cash $1.2B; pipeline on track for 2025 pivotal data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.3M for Q3 2024; R&D expenses $60.6M, G&A $15.8M.","Cash, cash equivalents and marketable securities $1.2B, expected to fund operations into 2028.","Zidesamtinib (ROS1+) Phase 1 data at ESMO; Phase 2 enrollment ongoing (227 patients), pivotal data expected 2025.","NVL-655 (ALK+) Phase 2 enrollment ongoing (229 patients); ALKAZAR Phase 3 trial to start H1 2025.","Appointed Dr. Alice Shaw to Scientific Advisory Board; upsized public offering raised $575M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212898,"accession_number":"0001193125-24-220556","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvalent prices upsized $500M public offering of 5M shares at $100/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,000,000 shares at $100.00/share; gross proceeds ~$500M.","Net proceeds estimated at $469.5M; ~$540M if underwriters exercise 750k-share option.","Underwriters granted 30-day option for up to 750k additional shares at same price.","Proceeds expected to fund operating expenses and capital expenditures into 2028.","Closing expected on September 18, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212897,"accession_number":"0001193125-24-219153","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvalent reports promising Phase 1 data for zidesamtinib and NVL-655; pivotal data expected 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zidesamtinib ORR 44% in pre-treated ROS1+ NSCLC; 72% in G2032R mutation subset.","NVL-655 at RP2D showed ORR 38% in pre-treated ALK+ NSCLC; 64% in compound mutation patients.","Phase 2 enrollment accelerated: 227 patients in ARROS-1, 229 in ALKOVE-1 as of Sept 1, 2024.","Phase 3 ALKAZAR trial of NVL-655 vs alectinib in TKI-naïve ALK+ NSCLC to start H1 2025; FDA aligned.","Pivotal data from both Phase 2 trials now expected in 2025; no discontinuations due to TRAEs for zidesamtinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212896,"accession_number":"0000950170-24-093278","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports $658M cash, FDA breakthrough therapy for two candidates, net loss $57.2M in Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $658.0M as of June 30, 2024; operating runway into 2027.","Net loss $57.2M for Q2 2024; R&D expense $49.2M, G&A $16.0M.","FDA breakthrough therapy designation for zidesamtinib (ROS1) and NVL-655 (ALK).","Phase 2 enrollment ongoing for ALKOVE-1 (NVL-655) and ARROS-1 (zidesamtinib) with registrational intent; ESMO updates September 14.","Initiated HEROEX-1 Phase 1a/1b trial for NVL-330 in HER2-altered NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212895,"accession_number":"0000950170-24-085044","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuvalent doses first patient in Phase 1 trial of HER2-selective inhibitor NVL-330 for NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated HEROEX-1 Phase 1a/1b trial evaluating NVL-330 in pre-treated patients with HER2-altered NSCLC.","First patient dosed on July 22, 2024; trial will assess safety, tolerability, PK, and preliminary anti-tumor activity.","Trial objectives include determination of recommended Phase 2 dose (RP2D) for NVL-330."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231976,"accession_number":"0000950170-24-073632","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvalent 2024 annual meeting passes all proposals, elects three directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected three Class III directors (Conley, Srivastava, Wheeler) with >53M votes each.","Say-on-pay proposal approved with 55.8M 'For' votes (97.7% of votes cast excluding broker non-votes).","Annual frequency for say-on-pay approved with 56.8M votes for 1-year; board will hold annual advisory votes.","Ratification of KPMG as independent auditor for FY2024 approved with 57.4M votes (99.98% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231975,"accession_number":"0000950170-24-061087","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA grants Breakthrough Therapy designation to Nuvalent's NVL-655 for ALK+ NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NVL-655 received FDA Breakthrough Therapy designation for ALK-positive non-small cell lung cancer.","Designation covers patients with locally advanced or metastatic disease after two or more prior ALK TKIs.","Breakthrough Therapy status may accelerate development and FDA review for serious conditions.","Announcement date: May 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231974,"accession_number":"0000950170-24-056223","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q1 net loss of $44.5M; cash $691.8M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss of $44.5M; R&D expense $38.6M, G&A $14.0M.","Cash, cash equivalents and marketable securities $691.8M as of March 31, 2024; runway into 2027.","Updated data from ARROS-1 (ROS1) and ALKOVE-1 (ALK) trials expected at a medical meeting in H2 2024.","Phase 1 trial for HER2 program (NVL-330) expected to initiate in 2024.","Plans to outline front-line development strategy for ALK program in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250257,"accession_number":"0000950170-24-020604","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q4 net loss $38.3M; cash $719.9M; NVL-520 gets FDA BTD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $719.9M at Dec 31, 2023; operating runway into 2027.","Q4 net loss $38.3M, full year 2023 net loss $126.2M; R&D expenses $35.6M Q4 and $113.2M full year.","FDA granted Breakthrough Therapy Designation to NVL-520 for ROS1+ NSCLC after 2+ prior TKIs.","Initiated Phase 2 of ALKOVE-1 trial for NVL-655 at 150 mg once daily with registrational intent.","Expect to initiate Phase 1 for HER2 program in 2024; promoted Matthew Metivier to SVP HR."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250256,"accession_number":"0000950170-24-003376","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports $719.9M cash; launches 'OnTarget 2026' plan targeting first approval in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $719.9M as of Dec 31, 2023 (unaudited); expected to fund operations into 2027.","OnTarget 2026 plan aims for first potential approved product in 2026, with pivotal data from at least one lead program in 2025.","2024 milestones: advance Phase 2 ARROS-1 (NVL-520) and initiate Phase 2 ALKOVE-1 (NVL-655), launch front-line ALK strategy, start Phase 1 for HER2 program.","Interim data from ARROS-1 and ALKOVE-1 expected at medical meetings in 2024.","Company to present at J.P. Morgan Healthcare Conference on Jan 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267796,"accession_number":"0000950170-23-063338","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent Q3 net loss $33.6M; cash runway into 2027 after $300M offering; ALK/ROS1 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.6M ($0.59 per share) for Q3 2023; R&D expenses $29.6M, G&A $9.2M.","Cash, equivalents and marketable securities $413.3M at Sept 30; plus $282M net from Oct 2023 offering, runway to 2027.","Reported preliminary Phase 1 data for NVL-655 (ALK+) showing activity in heavily pre-treated patients with favorable safety.","Initiated Phase 2 registrational cohorts for NVL-520 (ROS1+) at 100 mg daily; data update expected in 2024.","Appointed Perrin Wilson, Ph.D., as SVP of Business Development & Strategy; advancing NVL-330 toward IND."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267795,"accession_number":"0001193125-23-257651","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvalent prices $300M public offering of 5.36M shares at $56.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,357,143 shares at $56.00 each; gross proceeds ~$300M.","Net proceeds est. ~$281.6M (or ~$323.9M if underwriters exercise option for 803,571 additional shares).","Underwriters: J.P. Morgan, TD Cowen, Piper Sandler, BMO Capital Markets; close expected Oct 19, 2023.","Company expects net proceeds + existing cash to fund operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267794,"accession_number":"0001193125-23-255616","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvalent reports Phase 1 ALKOVE-1 data: NVL-655 shows 39% ORR in heavily pre-treated ALK+ NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 39% (20/51) in response-evaluable NSCLC patients; 44% (18/41) at ≥50 mg QD dose levels.","Activity in CNS metastases subgroup: ORR 52% (15/29); all responders continued without CNS progression.","Patients with ALK G1202R mutations had 71% ORR (12/17); compound mutations ORR 56% (9/16).","Favorable safety: 2% discontinuations, 5% dose reductions; no TRK-related neurotoxicities; MTD not reached.","100% clearance of ALK resistance mutations in 14/16 patients with G1202R or I1171X mutations by ctDNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267793,"accession_number":"0001193125-23-250724","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvalent reports NVL-655 Phase 1 data: 45% ORR in evaluable ALK+ NSCLC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["57 patients received 15–200 mg once daily; 51% had baseline CNS metastases; 77% post-lorlatinib.","ORR 45% (15/33) in evaluable ALK+ NSCLC; 65% (11/17) in patients with ALK resistance mutations.","41% ORR (12/29) in post-lorlatinib patients, including those with compound resistance mutations.","No MTD identified; most common TRAEs: nausea (12%), transaminase elevation (12%), fatigue (9%).","Updated data to be presented Oct 13 at AACR-NCI-EORTC; company to host conference call that day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285021,"accession_number":"0000950170-23-040936","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent Q2 net loss $29.1M; cash $431.2M; NVL-655 data expected Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.1M ($0.51/share); R&D $25.9M, G&A $8.1M for Q2 2023.","Cash, cash equivalents and marketable securities $431.2M as of June 30, 2023; runway into H2 2025.","Preliminary dose-escalation data for NVL-655 from ALKOVE-1 trial expected at medical meeting in Q4 2023.","NVL-520 ARROS-1 trial progressing toward RP2D; NVL-330 HER2 inhibitor advancing through IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304844,"accession_number":"0000950170-23-028601","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Nuvalent holders elect directors, ratify KPMG, approve officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class II directors elected: Gary Gilliland, Michael Meyers, Joseph Pearlberg, Matthew Shair; all received majority support.","KPMG LLP ratified as independent auditor for fiscal year ending Dec 31, 2023, with 48.9M for, 0.1M against.","Stockholders approved charter amendment to adopt Delaware officer exculpation provisions, effective June 15, 2023.","Annual meeting had 49.0M shares present, representing ~95.5% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304843,"accession_number":"0000950170-23-020806","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q1 2023 net loss of $25.2M; NVL-655 Phase 1 data expected H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.2M ($0.44 per share) for Q1 2023.","Cash, cash equivalents and marketable securities of $450.5M; runway into H2 2025.","R&D expenses $22.1M, G&A expenses $8.1M for Q1 2023.","Preliminary dose-escalation data for NVL-655 (ALK inhibitor) from ALKOVE-1 trial expected H2 2023.","NVL-520 (ROS1) Phase 1 enrollment ongoing; NVL-330 (HER2) in IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324369,"accession_number":"0000950170-23-008282","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports net loss of $81.9M for FY22; cash runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $472.2M as of Dec 31, 2022; expected to fund operations into H2 2025.","Net loss of $26.1M in Q4 2022 and $81.9M for full year 2022; R&D expenses $63.7M (FY) vs $35.6M in 2021.","Pipeline progress: NVL-520 Phase 1 data supportive of best-in-class profile in ROS1+ NSCLC; NVL-655 Phase 1 enrolling; NVL-330 (HER2 exon20) nominated as development candidate.","Leadership promotions: Henry Pelish to SVP Drug Discovery; John Soglia to SVP Translational Development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324368,"accession_number":"0001193125-23-067930","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nuvalent says exposure to Silicon Valley Bank is immaterial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDIC took control of Silicon Valley Bank on March 10, 2023.","Nuvalent reviewed its accounts and believes current exposure is immaterial.","Company will continue to assess impact of SVB receivership.","No specific dollar amounts or account balances disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342273,"accession_number":"0001564590-22-037280","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent Q3 net loss $19.7M; NVL-520 shows proof-of-concept; $264.5M offering extends runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $19.7M ($0.41/sh); cash $240.1M; with $264.5M offering extends runway into H2 2025.","NVL-520 Phase 1 data: no DLTs, activity in heavily pre-treated ROS1+ NSCLC including G2032R and brain metastases.","NVL-655 (ALK inhibitor) enrollment in Phase 1 ALKOVE-1 trial progressing; new preclinical data shows activity against compound mutations.","NVL-330 (HER2 exon 20) preclinical data demonstrates potency, selectivity, brain penetration; potential best-in-class."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342272,"accession_number":"0001193125-22-275066","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nuvalent prices $230M public offering of 6.87M shares at $33.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,865,672 shares of Class A common stock priced at $33.50/share; gross proceeds ~$230M.","Underwriters granted 30-day option to purchase up to an additional 1,029,850 shares.","Offering expected to close November 3, 2022, subject to customary conditions.","Company also amended ATM facility, reducing maximum aggregate offering to $135M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342271,"accession_number":"0001193125-22-271664","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuvalent reports preliminary Phase 1 data for NVL-520: 48% ORR in heavily pre-treated ROS1+ NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["48% ORR (10/21) in heavily pre-treated ROS1+ NSCLC; 78% (7/9) in G2032R mutation patients.","Intracranial PRs in 100% (3/3) with measurable CNS mets; 73% (8/11) with CNS history.","No DLTs, treatment-related SAEs, dizziness, or AEs leading to dose reduction/discontinuation in 35 patients.","Dose levels 25-125 mg QD achieved exposures above target thresholds; half-life supports once-daily dosing.","Phase 1 enrollment ongoing; 76% (16/21) of response-evaluable patients continue treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342270,"accession_number":"0001564590-22-033704","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuvalent elects Dr. Michael L. Meyers to the Board as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Meyers was elected independent Class II director effective October 4, 2022.","He will also serve on the Nominating and Corporate Governance Committee.","Received initial option grant for 40,000 shares at $19.48 per share, vesting monthly over 3 years.","Compensation follows Nuvalent's non-employee director policy including annual cash retainers and equity.","No family relationships or transactions with the Company requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359029,"accession_number":"0001564590-22-028853","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q2 2022 net loss of $18.5M; pipeline on track with NVL-520 data expected H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.5M ($0.38 per share); cash, equivalents and marketable securities $257.0M expected to fund operations into 2024.","R&D expenses $13.6M, G&A $5.2M for Q2 2022.","Preliminary dose-escalation data from Phase 1 ARROS-1 trial (NVL-520 for ROS1+ NSCLC) anticipated in H2 2022.","Dosing initiated in Phase 1 ALKOVE-1 trial (NVL-655 for ALK+ NSCLC); new preclinical data presented at WCLC 2022.","On track to select two additional development candidates in H2 2022 for ALK compound resistance mutations and HER2 Exon 20 insertions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377842,"accession_number":"0001564590-22-023767","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuvalent stockholders elect three Class I directors and ratify KPMG as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors elected: Andrew A.F. Hack (36,826,171 for, 3,083,308 withheld), James R. Porter (37,833,013 for, 2,076,466 withheld), Anna Protopapas (39,862,069 for, 47,410 withheld).","Ratification of KPMG as independent auditor for FY 2022: 39,976,244 for, 1,000 against, 1 abstain.","Approximately 93.23% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377841,"accession_number":"0001564590-22-019665","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports Q1 net loss $17.5M; cash $272.7M; ALK trial expected Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.5M ($0.36 diluted EPS); R&D expenses $12.7M, G&A $5.0M.","Cash, cash equivalents and marketable securities of $272.7M; expected to fund operations into 2024.","IND for NVL-655 (ALK) cleared; ALKOVE-1 Phase 1/2 trial anticipated to begin Q2 2022.","On track to select two additional development candidates in 2022 (ALK resistance mutations and HER2 exon 20).","Appointed Anna Protopapas as Chair of Board of Directors in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396148,"accession_number":"0001193125-22-090644","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuvalent appoints Anna Protopapas as independent Board Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anna Protopapas elected as Class I director and Board Chair, effective March 30, 2022.","Protopapas is independent under Nasdaq rules; no committee assignments at this time.","Received initial option grant for 40,000 shares at $14.08 exercise price, vesting over three years.","Compensation per non-employee director policy; also eligible for annual cash retainers and equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396147,"accession_number":"0001193125-22-087372","cik":1861560,"company_name":"Nuvalent, Inc.","ticker":"NUVL","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuvalent reports $17.3M Q4 loss; IND cleared for ALK inhibitor NVL-655","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net loss $17.3M; full-year net loss $46.3M, vs $14.6M in 2020.","Cash, equivalents, marketable securities $288.1M as of Dec 31, 2021; runway into 2024.","FDA cleared IND for NVL-655 (ALK-selective); ALKOVE-1 Phase 1/2 to start Q2 2022.","ARROS-1 trial of NVL-520 (ROS1) actively enrolling Phase 1 patients.","Discovery pipeline targeting ALK resistance and HER2 exon 20; 2 candidate nominations expected in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8478451745.409528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-29T23:59:59+00:00|396147"}